TRIUMPH-1 Phase 3 Trial Results and Side Effects Retatrutide's TRIUMPH-1 results indicate that the drug may deliver unprecedented weight loss results among available treatments
This study proves that our patch can deliver a high enough drug load for therapeutic effect, breaking through the limitations of previous obesity microneedle technology, said Kang Bok-ki, CEO of Daewoong Therapeutics
Many patients find it easier to reduce portions and choose healthier foods once their hunger signals are controlled
Medicare Part D does not cover GLP-1 medications prescribed for weight loss regardless of other prescriptions
Mean body weight reduction reached approximately 24 percent at the highest dose tier a magnitude that, investigators have noted, exceeds the Phase 2 outcomes reported for dual GLP-1/GIP agonists at comparable trial durations (PMID 37366315)
The most common side effects of Semaglutide/Tirzepatide/Retatrutide may include_ Nausea, heartburn, diarrhea, constipation, stomach pain, headache, fatigue, exercise intolerance, upset stomach, dizziness, bloating, belching, and gas
